Therapeutics News and Research

RSS

UNMCC receives NCI Comprehensive Cancer Center designation for cancer treatment, research programs

The University of New Mexico Cancer Center has been awarded the highest designation and rating in the United States for cancer treatment and research programs. It has received the National Cancer Institute's "NCI Comprehensive Cancer Center" designation, identifying it as one of the leading cancer centers in the nation and the only such cancer center in New Mexico.

13 Aug 2015

Echo's non-invasive CGM system to be designated as Class 2 medical device in China

Echo Therapeutics, Inc., a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that, after numerous consultations with the Chinese government, its strategic partner, Medical Technologies Innovation Asia, Ltd., believes that Echo's locally produced needle-free CGM products will be designated as a Class 2 medical device.

12 Aug 2015

CMC Biologics, PATH Malaria Vaccine Initiative sign agreement for development of specific monoclonal antibodies

CMC Biologics, a global leader in clinical and commercial development and contract manufacture of therapeutic proteins, announced today it has entered into an agreement with the PATH Malaria Vaccine Initiative (MVI) for process development and manufacture of specific monoclonal antibodies to test for their capacity to protect humans from malaria infection.

12 Aug 2015

Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2015.

12 Aug 2015

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy in patients with localized renal cell carcinoma.

11 Aug 2015

Sorrento, TNK Therapeutics to exclusively license NanoVelcro CTC assay from CytoLumina and FetoLumina

Sorrento Therapeutics, Inc. announced today that it as well as its wholly-owned subsidiary TNK Therapeutics, Inc. have entered into a binding term sheet to exclusively license the NanoVelcro Circulating Tumor Cell (CTC) profiling assay technology from CytoLumina Technologies Corp. and FetoLumina Technologies Corp., two privately-held sister biotechnology companies in Los Angeles, California.

11 Aug 2015

New technology advances genome engineering

In his mind, Basil Hubbard can already picture a new world of therapeutic treatments for millions of patients just over the horizon. It's a future in which diseases like muscular dystrophy, cystic fibrosis and many others are treated permanently through the science of genome engineering.

11 Aug 2015

Deerfield provides $20 million financing to Editas Medicine

Deerfield Management Company, L.P.'s venture capital fund, Deerfield Healthcare Innovations Fund, L.P., today announced its first therapeutics-based investment by participating, along with Deerfield Private Design Fund III, in providing financing to Editas Medicine. In total, Deerfield invested $20 million in this early-stage institutional financing.

10 Aug 2015

Impax sells U.S. rights to Daraprim brand for $55 million to Turing Pharmaceuticals

Impax Laboratories, Inc. today announced that it has sold its U.S. rights to the Daraprim brand to Turing Pharmaceuticals AG for approximately $55 million.

10 Aug 2015

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Intrexon Corporation, a leader in synthetic biology, and Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced an Exclusive Channel Collaboration (ECC) to pursue the development and commercialization of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder.

10 Aug 2015

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

Sorrento Therapeutics, Inc. announced today that its wholly-owned subsidiary, TNK Therapeutics, Inc., has acquired multiple preclinical and clinical stage chimeric antigen receptor (CAR)-T immunotherapy programs as well as underlying CAR-T technology through the acquisition of two privately-held biotechnology companies.

10 Aug 2015

GenVec reports net loss of $1.9 million for second quarter 2015

GenVec, Inc. today reported financial results for the second quarter ended June 30, 2015. For the three months ended June 30, 2015, GenVec reported a net loss of $1.9 million, or $0.11 per share, on revenues of $0.1 million, compared with a net loss of $1.7 million, or $0.10 per share, on revenues of $0.1 million, for the same period in the prior year.

7 Aug 2015

UNC researchers show how a genetic mutation disables molecular switch and causes autism

Last December, researchers identified more than 1,000 gene mutations in individuals with autism, but how these mutations increased risk for autism was unclear. Now, UNC School of Medicine researchers are the first to show how one of these mutations disables a molecular switch in one of these genes and causes autism.

7 Aug 2015

Neovasc's second quarter revenues drop 18%

Neovasc Inc. today announced financial results for the quarter ended June 30, 2015.

6 Aug 2015

Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

Antiva Biosciences, Inc. (formerly Hera Therapeutics), a biopharmaceutical company developing antiviral therapeutics, today announced that it has raised $16 million in a Series B financing, its first institutional round.

6 Aug 2015

Heptares, AstraZeneca sign licensing agreement to develop and commercialise immuno-oncology treatments

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.

6 Aug 2015

AmpliPhi provides update on cGMP manufacturing facility and investigational bacteriophage cocktail for treating S. aureus

AmpliPhi BioSciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that the Company will give a presentation today at the 21st Biennial Evergreen International Phage Meeting, taking place August 2-7 in Olympia, Wash.

6 Aug 2015

Penn research reveals additional pathway for origin of colon cancer

Cancer researchers already know of some oncogenes and other factors that promote the development of colon cancers, but they don't yet have the full picture of how these cancers originate and spread. Now researchers from the Perelman School of Medicine at the University of Pennsylvania have illuminated another powerful factor in this process.

6 Aug 2015

Scientists use highly specialized X-ray crystallography technique to solve protein structure of HIFs

In a collaborative study between Sanford Burnham Prebys Medical Discovery Institute and the Argonne National Laboratory, scientists have used a highly specialized X-ray crystallography technique to solve the protein structure of hypoxia-inducible factors (HIFs), important regulators of a tumor's response to low oxygen (hyopoxia).

6 Aug 2015

TSRI study shows single injection of blebbistatin drug prevents methamphetamine relapse in animal models

Recovering addicts often grapple with the ghosts of their addiction—memories that tempt them to relapse even after rehabilitation and months, or even years, of drug-free living.

5 Aug 2015

Therapeutics News and Research

UNMCC receives NCI Comprehensive Cancer Center designation for cancer treatment, research programs

Echo's non-invasive CGM system to be designated as Class 2 medical device in China

CMC Biologics, PATH Malaria Vaccine Initiative sign agreement for development of specific monoclonal antibodies

Ardelyx reports net income of $9.0 million for second quarter 2015

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Sorrento, TNK Therapeutics to exclusively license NanoVelcro CTC assay from CytoLumina and FetoLumina

New technology advances genome engineering

Deerfield provides $20 million financing to Editas Medicine

Impax sells U.S. rights to Daraprim brand for $55 million to Turing Pharmaceuticals

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

GenVec reports net loss of $1.9 million for second quarter 2015

UNC researchers show how a genetic mutation disables molecular switch and causes autism

Neovasc's second quarter revenues drop 18%

Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

Heptares, AstraZeneca sign licensing agreement to develop and commercialise immuno-oncology treatments

AmpliPhi provides update on cGMP manufacturing facility and investigational bacteriophage cocktail for treating S. aureus

Penn research reveals additional pathway for origin of colon cancer

Scientists use highly specialized X-ray crystallography technique to solve protein structure of HIFs

TSRI study shows single injection of blebbistatin drug prevents methamphetamine relapse in animal models

Next-generation therapeutics eBook eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News